Lack of Funding Drives Biotech to Suspend Drug-Resistant Antibiotic Pipeline
Despite the increasing need for antibiotics against drug-resistant bacteria, companies are finding it hard to make a play in the field due to lack of funding. Five-year-old X-Biotix announced it is throwing in the towel on its antibacterial research efforts and changing gears for its corporate strategy.
“This issue is driven by a critical lack of sustained sources of funding to support early-stage research in this field, combined with lack of an appropriate market infrastructure to support the successful commercialization of novel antibiotics,” said Stephen Isaacs, Chairman of X-Biotix.
After a successful Series A in 2018, X-Biotix was in the process of advancing a novel pipeline of first-in-class programs. Two programs directed against LpxA and LpxC, Gram-negative targets, validated a pathway for which there are currently no antibiotics available.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.